Smoking cessation 4: antidepressants for smoking cessation – bupropion and nortriptyline
Paul Aveyard, Amanda Parsons, Rachna Begh
Abstract
Paul Aveyard, Amanda Parsons, Rachna Begh
Abstract
Cigarette smoking remains the most preventable cause of illness, death and excess healthcare costs in the UK. Most smokers want to stop smoking and intend to stop at some point. In this fourth article in our occasional series on smoking cessation in primary care, we look at the evidence for the use of antidepressants, including bupropion, which is licensed for this indication, and nortriptyline, which is not.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Cigarette smoking remains the most preventable cause of illness, death and excess healthcare costs in the UK. Most smokers want to stop smoking and intend to stop at some point. In this fourth article in our occasional series on smoking cessation in primary care, we look at the evidence for the use of antidepressants, including bupropion, which is licensed for this indication, and nortriptyline, which is not.
Key concepts: Bupropion, Medicine, Nortriptyline, Smoking cessation, Psychiatry, Pharmacology, Amitriptyline, Pathology